Baird analyst Joel Beatty lowered the firm’s price target on Calidi to $4.50 from $9 and keeps an Outperform rating on the shares. The firm said its Q4 earnings call was uneventful in light of recent announcements and they continue to view Calidi as having a promising and differentiated oncolytic virotherapy program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDI:
- Calidi Biotherapeutics Issues Regulation FD Disclosure Notice
- Calidi Biotherapeutics Restructures Debt and Streamlines Finances
- Calidi Biotherapeutics Showcases Oncolytic Virotherapy Advances
- Calidi Biotherapeutics Resolves Dispute with Equity Settlement
- Calidi Biotherapeutics Resolves Stock Dispute with Physicians